GSK plc’s walk-away from refractory chronic cough prospect camlipixant because of dicey phase III results opened the door wider for Trevi Therapeutics Inc. with Haduvio...

Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The increased risk...

After decades of clinical research and false starts, have Brain-Computer Interface (BCI) systems finally arrived? Read BioWorld's special series.

Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai...